If you have any questions, ask your doctor or pharmacist. Some brands of this inhaler have a built-in sensor that can store data on its use. This information can be used with a smartphone ...

If you have any questions, ask your doctor or pharmacist. Some brands of this inhaler have a built-in sensor that can store data on its use. This information can be used with a smartphone ...

Seek medical attention immediately if treatment with Proair HFA becomes less effective, worse, and/or becomes more frequently used. Priming and Cleaning Instruct patients to prime the inhaler ...

Albuterol sulfate 90mcg/inh; dry pwd for oral inhalation (with a dose counter). <4yrs: not established. ≥4yrs: 2 inh every 4–6hrs; in some patients: 1 inh every 4hrs may suffice. Exercise ...

U.S. District Judge Stanley Chesler agreed with Amneal in June, finding the patents only cover parts of an inhaler device and "do not claim or even mention" ProAir HFA's active ingredient.

Teva has launched new digital inhaler and drug combination in the ... who can use the product branded as ProAir Digihaler (albuterol sulfate) for patients with asthma and chronic obstructive ...

ProAir HFA inhaler from the Food and Drug Administration’s Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on ...

The appellate court order stems from a case brought by Teva against drugmaker Amneal Pharmaceuticals (NYSE: AMRX) after the latter sought Food and Drug Administration (FDA) approval to bring a generic ...

[23] The Federal Circuit noted that “the fact that the FDA approved Teva’s ProAir® HFA combination product as a drug does not make the inhaler’s device parts a drug. They are still devices ...

The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...

The Federal Circuit's recent ruling that patents listed in the FDA's Orange Book must cover the active ingredient of a drug has sparked significant debate in the pharmaceutical industry. The court's ...